ReviewEmerging infectious diseases
What makes Cryptococcus neoformans a pathogen?
Review in Emerging infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 328 citations in OpenAlex.
- Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin.PLoS pathogens · 2011Trial
- A role for aquaporin (Aqp1) in the control of Cryptococcus neoformans cell morphology.The Journal of biological chemistry · 2026Article
- Polymorphic α-Glucans as Structural Scaffolds in Cryptococcus Cell Walls for Chitin, Capsule, and Melanin: Insights FromAngewandte Chemie (International ed. in English) · 2025Article
- An Optimized In-House Protocol forJournal of fungi (Basel, Switzerland) · 2025Article
- Involvement of CD146 in theInfection and immunity · 2025Article
- Research advances and public health strategies in China on WHO priority fungal pathogens.Mycology · 2025Review
- Evidence for the role of Irk2 and Irk5 in ATP and metabolism regulation inFrontiers in cellular and infection microbiology · 2025Article
- Integrative Proteome and Metabolomics Analyses of Cryptococcus neoformans Responses to Melanin Substrates Niger seed and L-DOPA.Current microbiology · 2024Article
- Design of an epitope-based peptide vaccine against Cryptococcus neoformans.FEBS open bio · 2024Article
- Progress in the application of nanoparticles for the treatment of fungal infections: A review.Mycology · 2024Review
- Non-self glycan structures as possible modulators of cancer progression: would polysaccharides from Cryptococcus spp. impact this phenomenon?Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Review
- Comprehensive genome-scale metabolic model of the human pathogenFrontiers in bioinformatics · 2023Article
- Clinical and pathological characterization of Central Nervous System cryptococcosis in an experimental mouse model of stereotaxic intracerebral infection.PLoS neglected tropical diseases · 2023Article
- Characteristics and Outcomes of Cryptococcosis among Patients with and without COVID-19.Journal of fungi (Basel, Switzerland) · 2022Article
- Article
- Article
- Pulmonary Fibrosis and Hypereosinophilia in TLR9Pathogens (Basel, Switzerland) · 2022Article
- Hemolymph of triatomines presents fungistatic activity againstThe journal of venomous animals and toxins including tropical diseases · 2022Article
- Raman Characterization of Fungal DHN and DOPA Melanin Biosynthesis Pathways.Journal of fungi (Basel, Switzerland) · 2021Article
- Effects of cigarette smoke extract on bronchial epithelial cells stimulated with Cryptococcus neoformans.Medical microbiology and immunology · 2021Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Life-threatening infections caused by the encapsulated fungal pathogen Cryptococcus neoformans have been increasing steadily over the past 10 years because of the onset of AIDS and the expanded use of immunosuppressive drugs. Intricate host-organism interactions make the full understanding of pathogenicity and virulence of C. neoformans difficult. We discuss the current knowledge of the characteristics C. neoformans must possess to enter the host and establish progressive disease: basic growth requirements and virulence factors, such as the polysaccharide capsule; shed products of the organism; melanin production; mannitol secretion; superoxide dismutase; proteases; and phospholipases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.